Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin

LEUKEMIA: (2003) 17, 468-470. doi:10.1038/sj.leu.2402749

Saved in:
Bibliographic Details
Published in:Leukemia 2003-02, Vol.17 (2), p.468-470
Main Authors: Zwaan, ChM, Reinhardt, D, Jürgens, H, Huismans, D R, Hählen, K, Smith, O P, Biondi, A, Wering, E R van, Feingold, J, Kaspers, G J L
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Aminoglycosides
Anti-Bacterial Agents - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antigens, CD - blood
Antigens, Differentiation, Myelomonocytic - blood
Calicheamicin
Cancer Research
Child
Child, Preschool
Chromosome Deletion
correspondence
Critical Care Medicine
Female
Gemtuzumab ozogamicin
Hematology
Humans
Immunotoxins - therapeutic use
Infant
Intensive
Internal Medicine
Karyotyping
Leukemia
Lymphatic leukemia
Male
Medicine
Medicine & Public Health
Oncology
Pediatrics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Sialic Acid Binding Ig-like Lectin 3
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:LEUKEMIA: (2003) 17, 468-470. doi:10.1038/sj.leu.2402749
ISSN:0887-6924
1476-5381
1476-5551
DOI:10.1038/sj.leu.2402749